<p>Crescent Biopharma（納斯達克代碼：CBIO - 獲取免費報告）於週四發佈了其財報。這家生物製藥公司報告本季度每股收益（EPS）為（$4.93），低於市場共識預期的（$2.69），差距為（$2.24），據 Zacks 報道。</p>
<p>獲取 <strong>Crescent Biopharma</strong> 的提醒：</p>
<h2>Crescent Biopharma 股價下跌 3.4%</h2>
<p>週五，CBIO 股票開盤價為 $12.00。該公司的市值為 $2.346 億，市盈率為 -0.34，貝塔值為 1.51。Crescent Biopharma 的 52 周最低價為 $11.06，52 周最高價為 $63.00。</p>
<h2>華爾街分析師觀點</h2>
<p>CBIO 一直是幾份分析報告的主題。TD Cowen 在 6 月 20 日的報告中將 Crescent Biopharma 的評級上調至 “強力買入”。Wedbush 在 7 月 14 日的研究報告中開始覆蓋 Crescent Biopharma，給予 “跑贏大盤” 評級，並設定 $27.00 的目標價。Wall Street Zen 在週六的研究報告中將 Crescent Biopharma 的評級從 “持有” 下調至 “賣出”。Lifesci Capital 在 6 月 18 日的研究報告中將 Crescent Biopharma 的評級上調至 “強力買入”，並設定 $22.00 的目標價。最後，Stifel Nicolaus 在 6 月 25 日的研究報告中開始覆蓋 Crescent Biopharma，給予 “買入” 評級，並設定 $28.00 的目標價。一位股票研究分析師給予該股 “賣出” 評級，兩位給予 “買入” 評級，兩位給予 “強力買入” 評級。根據 MarketBeat 的數據，Crescent Biopharma 的共識評級為 “買入”，平均目標價為 $25.67。</p>
<p><strong>查看我們最新的 CBIO 股票分析</strong></p>
<h2>關於 Crescent Biopharma</h2>
<p>（獲取免費報告）</p>
<p>Crescent Biopharma, Inc 是一家生物製藥公司，開發和設計小分子治療藥物以治療癌症。該公司成立於 2024 年 9 月 19 日，總部位於馬薩諸塞州沃爾瑟姆。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Crescent Biopharma</li>
<li>2022-2025 年股票市場假期 - 紐約證券交易所和納斯達克的休市時間</li>
<li>PG&amp;E 是 AI 的投資機會嗎？為什麼期權交易者在大舉押注</li>
<li>投資者如何從盤後交易中受益</li>
<li>MarketBeat 週迴顧 – 07/28 - 08/01</li>
<li>最活躍的股票：美元交易量與股票交易量</li>
<li>Hims &amp; Hers 會跟隨諾和諾德下跌嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0JJTw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Crescent Biopharma 嗎？</h2>
<p>在考慮 Crescent Biopharma 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Crescent Biopharma 並不在名單上。</p>
<p>雖然 Crescent Biopharma 目前在分析師中獲得 “強力買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CBIO

<p>Crescent Biopharma（納斯達克代碼：CBIO）報告的季度每股收益為（$4.93），低於市場共識預期的（$2.69），差距為（$2.24）。公告發布後，股價下跌 3.4%，開盤價為$12.00。該公司的市值為 2.346 億美元，市場共識評級為 “買入”，平均目標價為$25.67。分析師的評級各不相同，其中有一項賣出評級、兩項買入評級和兩項強烈買入評級。Crescent Biopharma 專注於開發用於癌症治療的小分子療法</p>

<p>Crescent Biopharma (NASDAQ:CBIO - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($4.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.69) by ($2.24), Zacks reports.</p>
<div class="lb-trans"><p>Crescent Biopharma（納斯達克代碼：CBIO - 獲取免費報告）於週四發佈了其財報。這家生物製藥公司報告本季度每股收益（EPS）為（$4.93），低於市場共識預期的（$2.69），差距為（$2.24），據 Zacks 報道。</p>
</div><p>Get <strong>Crescent Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Crescent Biopharma</strong> 的提醒：</p>
</div><h2>Crescent Biopharma Stock Down 3.4%</h2>
<div class="lb-trans"><h2>Crescent Biopharma 股價下跌 3.4%</h2>
</div><p>Shares of CBIO stock opened at $12.00 on Friday. The company has a market capitalization of $234.60 million, a price-to-earnings ratio of -0.34 and a beta of 1.51. Crescent Biopharma has a fifty-two week low of $11.06 and a fifty-two week high of $63.00.</p>
<div class="lb-trans"><p>週五，CBIO 股票開盤價為 $12.00。該公司的市值為 $2.346 億，市盈率為 -0.34，貝塔值為 1.51。Crescent Biopharma 的 52 周最低價為 $11.06，52 周最高價為 $63.00。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>CBIO has been the topic of several analyst reports. TD Cowen raised Crescent Biopharma to a &#34;strong-buy&#34; rating in a report on Friday, June 20th. Wedbush initiated coverage on Crescent Biopharma in a research note on Monday, July 14th. They issued an &#34;outperform&#34; rating and a $27.00 price objective on the stock. Wall Street Zen lowered Crescent Biopharma from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday. Lifesci Capital raised Crescent Biopharma to a &#34;strong-buy&#34; rating and set a $22.00 price objective on the stock in a research note on Wednesday, June 18th. Finally, Stifel Nicolaus initiated coverage on Crescent Biopharma in a research note on Wednesday, June 25th. They issued a &#34;buy&#34; rating and a $28.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Crescent Biopharma has a consensus rating of &#34;Buy&#34; and an average price target of $25.67.</p>
<div class="lb-trans"><p>CBIO 一直是幾份分析報告的主題。TD Cowen 在 6 月 20 日的報告中將 Crescent Biopharma 的評級上調至 “強力買入”。Wedbush 在 7 月 14 日的研究報告中開始覆蓋 Crescent Biopharma，給予 “跑贏大盤” 評級，並設定 $27.00 的目標價。Wall Street Zen 在週六的研究報告中將 Crescent Biopharma 的評級從 “持有” 下調至 “賣出”。Lifesci Capital 在 6 月 18 日的研究報告中將 Crescent Biopharma 的評級上調至 “強力買入”，並設定 $22.00 的目標價。最後，Stifel Nicolaus 在 6 月 25 日的研究報告中開始覆蓋 Crescent Biopharma，給予 “買入” 評級，並設定 $28.00 的目標價。一位股票研究分析師給予該股 “賣出” 評級，兩位給予 “買入” 評級，兩位給予 “強力買入” 評級。根據 MarketBeat 的數據，Crescent Biopharma 的共識評級為 “買入”，平均目標價為 $25.67。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on CBIO</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 CBIO 股票分析</strong></p>
</div><h2>About Crescent Biopharma</h2>
<div class="lb-trans"><h2>關於 Crescent Biopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.</p>
<div class="lb-trans"><p>Crescent Biopharma, Inc 是一家生物製藥公司，開發和設計小分子治療藥物以治療癌症。該公司成立於 2024 年 9 月 19 日，總部位於馬薩諸塞州沃爾瑟姆。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Crescent Biopharma</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>Is PG&amp;E an AI Power Play? Why Options Traders Are Betting Big</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>MarketBeat Week in Review – 07/28 - 08/01</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Will Hims &amp; Hers Fall Along With Novo Nordisk?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Crescent Biopharma</li>
<li>2022-2025 年股票市場假期 - 紐約證券交易所和納斯達克的休市時間</li>
<li>PG&amp;E 是 AI 的投資機會嗎？為什麼期權交易者在大舉押注</li>
<li>投資者如何從盤後交易中受益</li>
<li>MarketBeat 週迴顧 – 07/28 - 08/01</li>
<li>最活躍的股票：美元交易量與股票交易量</li>
<li>Hims &amp; Hers 會跟隨諾和諾德下跌嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Crescent Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Crescent Biopharma 嗎？</h2>
</div><p>Before you consider Crescent Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Crescent Biopharma 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Crescent Biopharma 並不在名單上。</p>
</div><p>While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Crescent Biopharma 目前在分析師中獲得 “強力買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Crescent Biopharma（NASDAQ:CBIO）公佈季度財報，每股收益比預期低 2.24 美元